Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 14/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780143 | 0.89 | CCR3 (0.47) | CCR3SLC6A2SLC6A4SLC6A3CCR2 | |
| SCHEMBL6774304 | 0.89 | CCR3 (0.47) | CCR3SLC6A2SLC6A4SLC6A3CCR2 | |
| SCHEMBL6774539 | 0.84 | RAB9A (0.56) | CCR3CNR1 | |
| SCHEMBL6772544 | 0.84 | RAB9A (0.56) | CCR3CNR1 | |
| SCHEMBL6774792 | 0.83 | CCR3 (0.55) | CCR3SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL6773109 | 0.83 | CCR3 (0.55) | CCR3SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL6768909 | 0.83 | CCR3 (0.50) | CCR3 | |
| SCHEMBL6769109 | 0.83 | CCR3 (0.50) | CCR3 | |
| SCHEMBL6772463 | 0.81 | CCR3 (0.70) | CCR3SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL6774937 | 0.79 | CCR3 (0.51) | CCR3SLC6A2SLC6A4SLC6A3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6441001-B1 | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-27 | — | — | US | disclosed |